SNO 2019: Dabrafenib + Trametinib Appears Promising in Recurrent or Refractory BRAF V600E‒Mutated High- and Low-Grade Glioma
Adverse events were manageable and no new safety signals were observed.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.